Skip to main content

Gilead Sciences Biktarvy revenue

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

Biktarvy revenue at Gilead Sciences came to $4.1B for the quarter to 30 Sep 2026, up 10.1% from a year earlier.

As Gilead Sciences reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$3.1BDec 2023$2.9BMar 2024$3.2BJun 2024$3.5BSep 2024$3.8BDec 2024$3.2BMar 2025$3.5BJun 2025$3.7BSep 2025$4.0BDec 2025$3.4BMar 2026$3.8BJun 2026$4.1BSep 2026
Gilead Sciences Biktarvy revenue, every reported period
Period endingBiktarvy revenueChange on a yearFiled
30 Sep 2026$4.1Bup 10.1%30 Oct 2026
30 Jun 2026$3.8Bup 6.9%6 Aug 2026
31 Mar 2026$3.4Bup 6.7%7 May 2026
31 Dec 2025$4.0Bup 5.1%24 Feb 2026
30 Sep 2025$3.7Bup 6.2%7 Nov 2025
30 Jun 2025$3.5Bup 9.2%7 Aug 2025
31 Mar 2025$3.2Bup 6.9%7 May 2025
31 Dec 2024$3.8Bup 21.4%28 Feb 2025
30 Sep 2024$3.5Bup 12.5%12 Nov 2024
30 Jun 2024$3.2Bup 8.5%8 Aug 2024
31 Mar 2024$2.9Bup 10.0%8 May 2024
31 Dec 2023$3.1Bup 6.5%23 Feb 2024
30 Sep 2023$3.1Bup 11.5%7 Nov 2023
30 Jun 2023$3.0Bup 16.5%4 Aug 2023
31 Mar 2023$2.7Bup 24.5%3 May 2023
31 Dec 2022$2.9Bup 15.3%22 Feb 2023
30 Sep 2022$2.8Bup 21.5%2 Nov 2022
30 Jun 2022$2.6Bup 28.2%8 Aug 2022
31 Mar 2022$2.2Bup 17.9%4 May 2022
31 Dec 2021$2.5Bup 22.2%23 Feb 2022
30 Sep 2021$2.3Bup 20.4%3 Nov 2021
30 Jun 2021$2.0Bup 24.3%5 Aug 2021
31 Mar 2021$1.8Bup 7.7%6 May 2021
31 Dec 2020$2.1Bup 31.9%25 Feb 2021
30 Sep 2020$1.9Bup 50.2%4 Nov 2020
30 Jun 2020$1.6Bup 43.7%6 Aug 2020
31 Mar 2020$1.7Bup 113.5%6 May 2020
31 Dec 2019$1.6B—25 Feb 2020
30 Sep 2019$1.3Bup 226.2%5 Nov 2019
30 Jun 2019$1.1Bup 503.2%6 Aug 2019
31 Mar 2019$793.0M—8 May 2019
30 Sep 2018$386.0M—6 Nov 2018
30 Jun 2018$185.0M—6 Aug 2018
31 Mar 2018$35.0M—9 May 2018
30 Sep 2017$0—7 Nov 2017
30 Jun 2017$0—7 Aug 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Gilead Sciences: Product sales · Descovy revenue · Trodelvy revenue · Genvoya revenue · Vemlidy revenue · Yeztugo revenue · Yescarta revenue · Odefsey revenue · Sofosbuvir/Velpatasvir revenue · Livdelzi revenue · Symtuza - Revenue share revenue · AmBisome revenue · Veklury revenue · Tecartus revenue · Royalty, contract and other revenues · United States revenue · Europe revenue · Rest of World revenue · financial statements

Every KPI and segment of GILD, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.